Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 905

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 905
---
ulated
    deficit 
     (29,137,721) 
     (21,285,062)
  
    Total
    stockholders’ equity 
     2,199,750  
     4,374,346 
  
    Total
    liabilities and stockholders’ equity 
    $2,923,099  
    $4,932,443 

See
notes to consolidated financial statements

F-4

MIRA
PHARMACEUTICALS, INC.

STATEMENTS
OF OPERATIONS

    2024  
    2023 

    Year
    Ended December 31, 

    2024  
    2023 
  
    Revenues 
    $-  
    $- 

    Operating
    costs: 

    General
    and administrative expenses 
     4,712,753  
     6,499,537 
  
    Related
    party travel costs 
     -  
     453,550 
  
    Research
    and development expenses 
     3,305,575  
     1,572,962 
  
    Total
    operating costs 
     8,018,328  
     8,526,049 

    Interest
    income (expense), net 
     165,669  
     (3,456,294)
  
    Net
    loss attributable to common stockholders 
    $(7,852,659) 
    $(11,982,343)
  
    Basic
    and diluted loss per share 
    $(0.51) 
    $(0.85)
  
    Basic
    weighted average common stock shares outstanding 
     15,444,149  
     13,924,619 

See
notes to consolidated financial statements

F-5

MIRA
PHARMACEUTICALS, INC.

STATEMENTS
OF CHANGES IN STOCKHOLDERS’ EQUITY(DEFICIT)

    Shares  
    Amount  
    Capital  
    Deficit  
    (Deficit) 

    Common
    Stock  
    Additional
                                                                  Paid-In  
    Accumulated  
    Total
                                                                  Stockholders’
                                                                  Equity 

    Shares  
    Amount  
    Capital  
    Deficit  
    (Deficit) 
  
    Balances,
    January 1, 2023